Pricing Log in Create free account

Madrigal Pharmaceuticals, Inc. (MDGL) vs Vaxcyte, Inc. (PCVX)

Madrigal Pharmaceuticals, Inc. and Vaxcyte, Inc. are both Biotechnology companies. Madrigal Pharmaceuticals, Inc. and Vaxcyte, Inc. are of similar size ($9.8B and $9.3B). Vaxcyte, Inc. has the higher net margin (0.00% vs −10.9%) and the higher return on invested capital (−57.3% vs −1,480.3%). Across the 14 metrics below, Vaxcyte, Inc. leads on 8 and Madrigal Pharmaceuticals, Inc. on 6.

Valuation

Metric MDGL PCVX Biotechnology median
P/E n/m n/m 10.26
P/S 8.19 n/m 9.18
P/B 18.66 3.28 2.05
Price to free cash flow n/m n/m 24.81
EV/EBITDA n/m n/m 0.65
EV/Sales 7.76 n/m 8.98
Earnings yield (1.48%) (12.20%) (34.89%)
Free cash flow yield (1.47%) (9.89%) (24.52%)

Profitability

Metric MDGL PCVX Biotechnology median
Gross margin 90.96% 0.00% 65.16%
Operating margin (10.69%) 0.00% 0.00%
Net margin (10.89%) 0.00% 0.00%
Free cash flow margin (11.81%) 0.00% 0.00%
Return on equity (24.82%) (36.51%) (50.12%)
Return on assets (11.12%) (33.03%) (45.60%)
Return on invested capital (1,480.32%) (57.30%) 0.00%

Growth

Metric MDGL PCVX Biotechnology median
Revenue growth (TTM) 92.80% — 6.26%
EPS growth (last fiscal year) 41.32% (48.16%) 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric MDGL PCVX Biotechnology median
Debt to equity 0.54 0.00 0.00
Current ratio 3.05 5.72 4.89
Net debt to EBITDA 2.21 1.71 1.01

Dividend

Metric MDGL PCVX Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric MDGL PCVX Biotechnology median
Market cap 9.29b 9.75b 172.11m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack